Inhibition of the ALK tyrosine kinase and its subsequent signal transduction pathway with specific TKI's results in tumor growth arrest, improved clinical response and a survival benefit in ALK-positive NSCLC as compared to WT NSCLC [24, 25, 26, 27, 28]. The gene discussed is ALK; the disease is neoplasm.